News
Xiromed LLC Announces Launch of EnilloRing® in the United States
Press Release Florham Park, NJ, October 3, 2023 Xiromed LLC today announced the launch of EnilloRing® (etonogestrel/ethinyl estradiol vaginal ring), a generic version of Nuvaring®. EnilloRing® is a contraceptive vaginal ring. “The launch of EnilloRing® is an exciting milestone in Xiromed’s journey to becoming a leading generic provider of women’s health care products in the […]
Xiromed LLC Launches Ramelteon Tablets
Press Release Florham Park, NJ, September 29th, 2023 Xiromed LLC today announced the launch of Ramelteon Tablets, 8mg, generic to Rozerem®. Xiromed’s product will be available in 30-count and 100-count bottles. Xiromed CEO Rob Spina commented, “Xiromed continues to expand its portfolio of generic pharmaceutical products with the launch of Ramelteon Tablets. We remain focused […]
Xiromed LLC Announces Launch of First-to-Market Generic Version of Balcoltra® in the U.S.
Press Release Florham Park, NJ, August 17 th , 2023 Xiromed LLC today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Joyeaux® (Levonorgestrel and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP), the first generic version of Balcoltra®. Joyeaux® is […]
Xiromed LLC Launches Betamethasone Valerate Foam, 0.12
Press Release Florham Park, NJ, August 2nd, 2023 Xiromed LLC today announced the launch of Betamethasone Valerate Foam, 0.12%, generic to Luxiq®. Annual market sales for Luxiq® and its generics for the twelve-month period ending June, 2023 were $4.4 million, according to IQVIA™. Betamethasone Valerate Foam, 0.12% is a medium potency topical corticosteroid indicated for […]
Xiromed LLC Launches Ephedrine Sulfate Injection USP, 50 mg/mL
Press Release Florham Park, NJ, July 17th, 2023 Xiromed LLC today announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, generic to Akovaz® in conjunction with its development partner, Aggrega Pharma. Ephedrine Sulfate Injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension […]
Xiromed LLC Launches Estradiol Valerate Injection, USP
Press Release Florham Park, NJ, May 1st, 2023 Xiromed LLC today announced that the U.S. Food and Drug Administration (FDA) has granted approval to its Abbreviated New Drug Application (ANDA) for Estradiol Valerate Injection, USP, generic to Delestrogen®. Xiromed’s Estradiol Valerate Injection, USP is available in 3 strengths: 10mg/mL (5mL), 20mg/mL (5mL) and 40mg/mL (5mL). […]
Xiromed LLC Launches Testosterone Cypionate Injection, USP
Press Release Florham Park, NJ, April 13th, 2023 Xiromed LLC today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection, USP, generic to Depo-Testosterone®. Xiromed will launch immediately. Annual market sales for Depo-Testosterone® and its generics for the twelve-month […]
Xiromed LLC Launches Estradiol Transdermal Gel 0.1% with a Competitive Generic Therapy (CGT) Designation
Florham Park, NJ, October 11th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Estradiol Transdermal Gel 0.1%, generic to Divigel®. Xiromed received final approval for its Abbreviated New Drug Application (ANDA) from the United States FDA with Competitive Generic Therapy (CGT) designation and is eligible for 180 […]
Xiromed LLC Launches Fulvestrant Injection 250 mg/5 mL (50 mg/mL)
Florham Park, NJ, September 12th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fulvestrant Injection 250 mg/5 mL (50 mg/mL), generic to Faslodex®. Annual market sales for Faslodex® and its generics for the twelve-month period ending July, 2022 were $101.4 million, according to IQVIA™. Rob Spina, CEO […]